Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.42 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25578509 | 0.86 | ENPP2 (0.43) | GRM2GRM3ENPP2DRD2DRD1 | |
| SCHEMBL6716632 | 0.84 | CTBP2 (0.45) | GRM2GRM3ENPP2SMN1; SMN2HIF1A | |
| SCHEMBL2212930 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2HIF1ATAAR1ARG1ARG2 | |
| SCHEMBL6724533 | 0.83 | GRM2 (0.47) | GRM2GRM3ENPP2SMN1; SMN2HIF1A | |
| SCHEMBL11016121 | 0.83 | GRM2 (0.47) | GRM2GRM3ENPP2SMN1; SMN2HIF1A | |
| SCHEMBL2892136 | 0.82 | SPR (0.43) | ENPP2DRD2DRD1TAAR1CYP1A2 | |
| SCHEMBL6716339 | 0.81 | ARG1 (0.51) | GRM2GRM3ENPP2DRD2DRD1 | |
| SCHEMBL22033172 | 0.80 | BLM (0.59) | SMN1; SMN2HIF1ACTBP2ARG1ARG2 | |
| SCHEMBL4245716 | 0.80 | BLM (0.59) | SMN1; SMN2HIF1ACTBP2ARG1ARG2 | |
| SCHEMBL4245719 | 0.80 | BLM (0.59) | SMN1; SMN2HIF1ACTBP2ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4342780-A | 2-AMINO-2-FLUOROMETHYL-3-(SUBSTITUTED) PHENYL PROPIONIC ACIDS AND DERIVATIVES COADMINISTERED WITH DOPAMINE | MERRELL-TORAUDE ET CIE (FR) | 1982-08-03 | — | — | US | claimed |
| US-12162902-B2 | Decarboxylase inhibitors for treating Parkinson's disease | SAIL BIOMEDICINES (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-08 | — | — | US | disclosed |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | SENDA BIOSCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | SENDA BIOSCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3891122-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-113302176-A | Decarboxylase inhibitors for the treatment of parkinson's disease | 先达生物科技公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020118163-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020118163-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-1814537-B1 | MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-11-12 | — | — | EP | disclosed |
| US-7678783-B2 | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080269302-A1 | Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2008-10-30 | — | — | US | disclosed |
| CN-101133029-A | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK & CO INC (US) | 2008-02-27 | — | — | CN | disclosed |
| EP-1814537-A2 | MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006055434-A2 | MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-4405530-A | Process for preparing fluorinated amino-nitriles | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-09-20 | — | — | US | disclosed |
| US-4342780-A | 2-AMINO-2-FLUOROMETHYL-3-(SUBSTITUTED) PHENYL PROPIONIC ACIDS AND DERIVATIVES COADMINISTERED WITH DOPAMINE | MERRELL-TORAUDE ET CIE (FR) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162902-B2 | Decarboxylase inhibitors for treating Parkinson's disease | DDC, DDT, DDO | GRM2 962/4885GRM3 1453/4885ENPP2 1378/4885 |
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PARK7, SNCA, RHOT2 | GRM2 517/4885GRM3 758/4885ENPP2 252/4885 |
| US-20080269302-A1 | Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN1 | GRM2 1389/4885GRM3 944/4885ENPP2 290/4885 |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | DDC, DDT, DDO | GRM2 962/4885GRM3 1453/4885ENPP2 1378/4885 |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | GRM2 436/4885GRM3 388/4885ENPP2 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.